Baupost Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Baupost Group’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,721,079	Closed	-$32.3M	–	36
2017 Q4	$32.3M	Hold	8,721,079	–	–	0.32%	26
2017 Q3	$35.7M	Hold	8,721,079	–	–	0.44%	28
2017 Q2	$32.4M	Hold	8,721,079	–	–	0.37%	30
2017 Q1	$36.1M	Buy	8,721,079 +4,554,413	+109%	+$19.1M	0.43%	35
2016 Q4	$18M	Sell	4,166,666 -1	-0%	-$6	0.23%	36
2016 Q3	$41M	Hold	4,166,667	–	–	0.58%	30
2016 Q2	$23.6M	Buy	+4,166,667	New	+$28.3M	0.32%	30

Baupost Group's CASC Position: Q1 2018 in Review

Baupost Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 8,721,079 shares — an estimated $32.3M sold.

Baupost Group first reported a position in CASC in Q2 2016 and held it in 7 quarters. The position peaked at $41M in Q3 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Baupost Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Baupost Group sold 8,721,079 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $32.3M.
Baupost Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
Baupost Group's Cascadian Therapeutics, Inc. position peaked at $41M in Q3 2016.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Baupost Group's 13F filing for Q1 2018, filed 14 May 2018.